This study is not yet accepting patients
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCLA
- Dates
- study startedcompletion around
- Principal Investigator
- by Gary Schiller, MD (ucla)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Gary Schiller, MD (ucla)
Professor-in-Residence, Medicine. Authored (or co-authored) 158 research publications
Details
- Status
- not yet accepting patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Stemline Therapeutics, Inc.
- ID
- NCT06456463
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- Expecting 76 study participants
- Last Updated